Abstract
Study design:
Male rats with complete transections of the spinal cord were administered vehicle or methylprednisolone (MP) for 24 h, with or without infusion, for 7 days, of testosterone at either a replacement or low pharmacological doses. Muscles were collected at 7 days after SCI.
Objective:
The objective of this study is to determine, in a rat model of complete spinal cord transection, whether testosterone reduces muscle atrophy or upregulates muscle atrophy-linked genes, induced by 24 h of MP administration at doses comparable to those prescribed in man during the period immediately following acute spinal cord injury (SCI) in an attempt to preserve neurological function.
Results:
MP significantly reduced the mass of triceps, soleus and plantaris, and significantly increased expression of genes that promote atrophy. Testosterone significantly reduced muscle atrophy induced by MP, but did not prevent it; there was no difference between low- or high-dose testosterone in reducing MP-induced muscle loss. High-dose testosterone reduced expression of muscle atrophy genes more than did low dose. Testosterone-induced declines in mRNA levels for these atrophy-associated genes did not correlate well with protection against MP-induced muscle atrophy.
Conclusions:
MP induces marked and lasting changes in the biology of muscle that persisted for at least 7 days, or 6 days after MP has been eliminated from the body. Testosterone partially protected against muscle atrophy and gene expression changes caused by 1 day of MP.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322: 1405–1411.
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997; 277: 1597–1604.
Suberviola B, Gonzalez-Castro A, Llorca J, Ortiz-Melon F, Minambres E . Early complications of high-dose methylprednisolone in acute spinal cord injury patients. Injury 2008; 39: 748–752.
Qian T, Guo X, Levi AD, Vanni S, Shebert RT, Sipski ML . High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord 2005; 43: 199–203.
Zhao W, Pan J, Zhao Z, Wu Y, Bauman WA, Cardozo CP . Testosterone protects against dexamethasone-induced muscle atrophy, protein degradation and MAFbx upregulation. J Steroid Biochem Mol Biol 2008; 110: 125–129.
Wu Y, Hou J, Collier L, Pan J, Hou L, Qin W et al. The administration of high-dose methylprednisolone for 24 h reduced muscle size and increased atrophy-related gene expression in spinal cord-injured rats. Spinal Cord 2011; 49: 867–873.
Prezant DJ, Karwa ML, Richner B, Maggiore D, Gentry EI, Chung V et al. Short-term vs long-term dexamethasone treatment: effects on rat diaphragm structure and function. Lung 1998; 176: 267–280.
Lewis MI, Monn SA, Sieck GC . Effect of corticosteroids on diaphragm fatigue, SDH activity, and muscle fiber size. J Appl Physiol 1992; 72: 293–301.
Wu Y, Zhao W, Zhao J, Zhang Y, Qin W, Pan J et al. REDD1 is a major target of testosterone action in preventing dexamethasone-induced muscle loss. Endocrinology 2010; 151: 1050–1059.
Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399–412.
Wang H, Kubica N, Ellisen LW, Jefferson LS, Kimball SR . Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem 2006; 281: 39128–39134.
Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704–1708.
Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab 2007; 6: 376–385.
Harvey KF, Mattila J, Sofer A, Bennett FC, Ramsey MR, Ellisen LW et al. FOXO-regulated transcription restricts overgrowth of Tsc mutant organs. J Cell Biol 2008; 180: 691–696.
Waddell DS, Baehr LM, van den Brandt J, Johnsen SA, Reichardt HM, Furlow JD et al. The glucocorticoid receptor and foxo1 synergistically activate the skeletal muscle atrophy associated Murf1 gene. Am J Physiol Endocrinol Metab 2008; 295: E785–E797.
Tsitouras PD, Zhong YG, Spungen AM, Bauman WA . Serum testosterone and growth hormone/insulin-like growth factor-I in adults with spinal cord injury. Horm Metab Res 1995; 27: 287–292.
Schopp LH, Clark M, Mazurek MO, Hagglund KJ, Acuff ME, Sherman AK et al. Testosterone levels among men with spinal cord injury admitted to inpatient rehabilitation. Am J Phys Med Rehabil 2006; 85: 678–684; quiz 685–7.
Reid IR, Ibbertson HK, France JT, Pybus J . Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. Br Med J (Clin Res Ed) 1985; 291: 574.
MacAdams MR, White RH, Chipps BE . Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104: 648–651.
Bracken MB, Holford TR . Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery in National Acute Spinal Cord Injury Study II from results modeled in National Acute Spinal Cord Injury Study III. J Neurosurg 2002; 96 (3 Suppl): 259–266.
Borst SE, Lee JH, Conover CF . Inhibition of 5alpha-reductase blocks prostate effects of testosterone without blocking anabolic effects. Am J Physiol Endocrinol Metab 2005; 288: E222–E227.
Zhao J, Zhang Y, Zhao W, Wu Y, Pan J, Bauman WA et al. Effects of nandrolone on denervation atrophy depend upon time after nerve transection. Muscle Nerve 2008; 37: 42–49.
Glass D, Roubenoff R . Recent advances in the biology and therapy of muscle wasting. Ann NY Acad Sci 2010; 1211: 25–36.
Fareed MU, Evenson AR, Wei W, Menconi M, Poylin V, Petkova V et al. Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1589–R1597.
Hazra A, Pyszczynski N, DuBois DC, Almon RR, Jusko WJ . Pharmacokinetics of methylprednisolone after intravenous and intramuscular administration in rats. Biopharm Drug Dispos 2007; 28: 263–273.
Almon RR, Dubois DC . Fiber-type discrimination in disuse and glucocorticoid-induced atrophy. Med Sci Sports Exerc 1990; 22: 304–311.
Van Balkom RH, Dekhuijzen PN, Folgering HT, Veerkamp JH, Van Moerkerk HT, Fransen JA et al. Anabolic steroids in part reverse glucocorticoid-induced alterations in rat diaphragm. J Appl Physiol 1998; 84: 1492–1499.
Inder WJ, Jang C, Obeyesekere VR, Alford FP . Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1 - implications for steroid-induced myopathy. Clin Endocrinol (Oxf) 2009; 73: 126–132.
Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 2003; 285: E363–E371.
Gilson H, Schakman O, Combaret L, Lause P, Grobet L, Attaix D et al. Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 2007; 148: 452–460.
Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269 (5 Part 1): E820–E826.
Wu Y, Zhao W, Zhao J, Pan J, Wu Q, Zhang Y et al. Identification of androgen response elements in the IGF-1 upstream promoter. Endocrinology 2007; 148: 2984–2993.
Kovacheva EL, Hikim AP, Shen R, Sinha I, Sinha-Hikim I . Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology 2010; 151: 628–638.
Acknowledgements
This research was supported by the Veterans Health Administration, Rehabilitation Research and Development Service (B4162C and B3347 K).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Wu, Y., Collier, L., Pan, J. et al. Testosterone reduced methylprednisolone-induced muscle atrophy in spinal cord-injured rats. Spinal Cord 50, 57–62 (2012). https://doi.org/10.1038/sc.2011.91
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sc.2011.91
